Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18697895 | 0.79 | TSHR (0.43) | TSHRACHEHPGDERCC5FEN1 | |
| SCHEMBL1029640 | 0.79 | HPGD (0.50) | HPGDERCC5FEN1HTTSMN1; SMN2 | |
| SCHEMBL5426379 | 0.79 | TSHR (0.43) | TSHRACHEHPGDERCC5FEN1 | |
| Iodide SCHEMBL18916733 | 0.77 | TSHR (0.41) | TSHRACHEHPGDERCC5FEN1 | |
| SCHEMBL14979489 | 0.77 | TSHR (0.41) | TSHRACHEHPGDERCC5FEN1 | |
| SCHEMBL2038760 | 0.77 | ACHE (0.53) | TSHRACHEHPGDERCC5FEN1 | |
| SCHEMBL23180243 | 0.75 | TSHR (0.39) | TSHRACHEHPGDERCC5FEN1 | |
| SCHEMBL26517902 | 0.75 | TSHR (0.39) | TSHRACHEHPGDERCC5FEN1 | |
| SCHEMBL2451836 | 0.74 | TSHR (0.50) | TSHRACHEHPGDERCC5FEN1 | |
| SCHEMBL39369 | 0.74 | TSHR (0.50) | TSHRACHEHPGDERCC5FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608687-B2 | Releasable linkage and compositions containing same | ALZA CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-7592307-B2 | Releasable linkage and compositions containing same | ALZA CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080279922-A1 | Releasable linkage and compositions containing same | ALZA CORPORATION | 2008-11-13 | — | — | US | disclosed |
| US-20080152702-A1 | Releasable linkage and compositions containing same | ZALIPSKY SAMUEL | 2008-06-26 | — | — | US | disclosed |
| EP-1880736-A1 | Releasable linkage and composition containing same | Alza Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7285622-B2 | Releasable linkage and compositions containing same | ALZA CORPORATION (US) | 2007-10-23 | — | — | US | disclosed |
| US-7238368-B2 | Releasable linkage and compositions containing same | ALZA CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1701744-A2 | THIOL-CLEAVABLE LINKAGE BETWEEN POLYMER AND LIGAND | ALZA CORPORATION (US) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005053749-A2 | THIOL-CLEAVABLE LINKAGE BETWEEN POLYMER AND LIGAND | ALZA CORPORATION (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20050123597-A1 | Releasable linkage and compositions containing same | ALZA CORPORATION | 2005-06-09 | — | — | US | disclosed |
| US-6849270-B2 | Releasable linkage and compositions containing same | ALZA CORPORATION (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040213759-A1 | Releasable linkage and compositions containing same | ALZA CORPORATION | 2004-10-28 | — | — | US | disclosed |
| US-20030211079-A1 | Releasable linkage and compositions containing same | ALZA CORPORATION | 2003-11-13 | — | — | US | disclosed |
| US-6605299-B2 | Hydrophilic polymer covalently and reversibly linked to amine-containing ligand through dithiobenzyl linkage; improves blood circulation time | ALZA CORPORATION | 2003-08-12 | — | — | US | disclosed |
| US-20020128195-A1 | Releasable linkage and compositions containing same | ALZA CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-6342244-B1 | HYDROPHILIC POLYMER COVALENTLY YET REVERSIBLY LINKED TO A AMINE-CONTAINING LIGAND THROUGH A DITHIOBENZYL LINKAGE; MODIFICATION OF VARIOUS SUBSTRATES, SUCH AS POLYPEPTIDES, DRUGS AND LIPOSOMES; UPON CLEAVAGE OF THE LINKAGE, THE LIGAND | ALZA CORPORATION | 2002-01-29 | — | — | US | disclosed |
| EP-1173221-A2 | RELEASABLE LINKAGE AND COMPOSITIONS CONTAINING SAME | Alza Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064483-A2 | RELEASABLE LINKAGE AND COMPOSITIONS CONTAINING SAME | ALZA CORPORATION (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211079-A1 | Releasable linkage and compositions containing same | CD44, ILK, CD69 | TSHR 3735/4885ACHE 26/4885HPGD 1261/4885 |
| US-20020128195-A1 | Releasable linkage and compositions containing same | CD44, ILK, CD69 | TSHR 3735/4885ACHE 26/4885HPGD 1261/4885 |
| US-20050123597-A1 | Releasable linkage and compositions containing same | CD44, ILK, CD69 | TSHR 3735/4885ACHE 26/4885HPGD 1261/4885 |
| US-20080279922-A1 | Releasable linkage and compositions containing same | CD44, SHMT1, HCAR1 | TSHR 3189/4885ACHE 263/4885HPGD 561/4885 |
| US-20080152702-A1 | Releasable linkage and compositions containing same | CD44, ILK, CD69 | TSHR 3735/4885ACHE 26/4885HPGD 1261/4885 |
| US-20040213759-A1 | Releasable linkage and compositions containing same | CD44, SHMT1, HCAR1 | TSHR 3189/4885ACHE 263/4885HPGD 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.